Oral Desmopressin in the Management of Adults with Nocturia

Shahram Gooran, Sevil Nasirmohtaram, Mohammad Ghasem Mohseni, Behzad Narouie

.

DOI: 10.4236/oju.2011.14015                

Abstract

We investigated the efficacy of oral desmopressin in the treatment of adult nocturia. In an analytical study between 2007-2009 in Zahedan-Iran, Thirty patients ≥55 years with verified nocturia (≥two voids/night) were enrolled. Patients with a history of an obstructive cause of nocturia, those with diseases getting worse by the anti-diuretic affect of desmopressin and those with well-defined curable causes (e.g. cystitis) were excluded. Patients received 0.2 mg of oral desmopressin at bed time for a period of 3 weeks. p < 0.05 was taken as the significant level. All 30 patients enrolled completed the trial. Fourteen (47 %) patients receiving desmopressin had fewer than half the number of nocturnal voids relative to base line (p < 0.001). The mean number of nocturnal voids decreased from 4.6 to 2.4 (p < 0.001). Fatigue (10%), headache (3%) and dizziness (3%) were reported. All adverse events were of mild intensity and there were no instances of hyponatremia. Oral desmopressin is an effective treatment in patients with nocturia and is well-tolerated.

Keywords

Nocturia, Desmopressin, Arginine Vasopressin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	P. van Kerrebroeck, P. Abrams, D. Chaikin, et al., “Standardisation Sub-Committee of the International Continence Society. The Standardisation of Terminology in Nocturia: Report from the Standardisation Sub-Committee of the International Continence Society,” Neurourology and Urodynamics, Vol. 21, No. 2, 2002, pp. 179-183. doi:10.1002/nau.10053
[2]	F. Y. Chen, Y. T. Dai, C. K. Liu, et al., “Perception of Nocturia and Medical Consulting Behavior among community-Dwelling Women,” International Urogynecology Journal and Pelvic Floor Dysfunction, Vol. 18, No. 4, 2007, pp. 431-436. doi:10.1007/s00192-006-0167-x
[3]	R. Lundgren, “Nocturia: A New Perspective on an Old Symptom,” Scandinavian Journal of Urology and Nephrology, Vol. 38, No. 2, 2004, pp. 112-116. doi:10.1080/00365590310020033
[4]	Y. Homma, “Classification of Nocturia in the Adult and Elderly Patient: A Review of Clinical Criteria and Selected Literature,” BJU International, Vol. 96, Supplement 1, 2005, pp. 8-14. doi:10.1111/j.1464-410X.2005.05655.x
[5]	R. B. Stewart, M. More, F. E. May, et al., “Nocturia a Risk Factor for Falls in the Elderly,” Journal of the American Geriatrics Society, Vol. 40, No. 12, 1992, pp. 1217-1220.
[6]	S. P. Marinkovic, L. M. Gillen and S. L. Stanton, “Managing Nocturia,” British Medical Journal, Vol. 328, No. 7447, 2004, pp. 1063-1066. doi:10.1136/bmj.328.7447.1063
[7]	R. Asplund and H. Aberg, “Diurnal Variation in the Levels of Antidiuretic Hormone in the Elderly,” Journal of Internal Medicine, 1991, Vol. 229, No. 2, pp. 131-134. doi:10.1111/j.1365-2796.1991.tb00320.x
[8]	R. Asplund, “The Nocturnal Polyuria Syndrome (NPS),” General Pharmacology, Vol. 26, No. 6, 1995, pp. 1203-1209. doi:10.1016/0306-3623(94)00310-J
[9]	M. Miller, “Nocturnal Polyuria in Older People: Pathophysiology and Clinical Implications,” Journal of the American Geriatrics Society, Vol. 48, No. 10, 2000, pp. 1321-1329.
[10]	J. L. Kirkland, M. Lye, D. W. Levy and A. K. Banerjee, “Patterns of Urine Flow and Electrolyte Excretion in Healthy Elderly People,” British Medical Journal (Clinical Research Ed.), Vol. 287, No. 6406, 1983, pp. 1665-1667. doi:10.1136/bmj.287.6406.1665
[11]	A. Mattiasson, P. Abrams, P. Van Kerrebroeck, et al., “Efficacy of Desmopressin in the Treatment of Nocturia: A Double-Blind Placebo-Controlled Study in Men,” BJU International, Vol. 89, No. 9, 2002, pp. 855-862. doi:10.1046/j.1464-410X.2002.02791.x
[12]	S. Hunskaar, “Epidemiology of Nocturia,” BJU International, Vol. 96, Supplement 1, 2005, pp. 4-7. doi:10.1111/j.1464-410X.2005.05650.x
[13]	H. Vilhardt, “Basic Pharmacology of Desmopressin: A Review,” Drug Investigation, Vol. 2, Supplement 5, 1990, pp. 2-8.
[14]	R. Asplund and H. Aberg, “Desmopressin in Elderly Subjects with Increased Nocturnal Diuresis. A Two-Month Treatment Study,” Scandinavian Journal of Urology and Nephrology, Vol. 27, No. 1, 1993, pp. 77-82. doi:10.3109/00365599309180419
[15]	R. Asplund, B. Sundberg and P. Bengtsson, “Oral Desmopressin for Nocturnal Polyuria in Elderly Subjects: A Double-Blind, Placebo-Controlled Randomized Exploratory Study,” BJU International, Vol. 83, No. 6, 1999, pp. 591-595. doi:10.1046/j.1464-410x.1999.00012.x
[16]	R. Asplund and H. Aberg, “Health of the elderly with regard to sleep and nocturnal micturition,” Scandinavian Journal of Primary Health Care, Vol. 10, No. 2, 1992, pp. 98-104. doi:10.3109/02813439209014044
[17]	S. B. Dimson, “Desmopressin as a Treatment for Enuresis,” The Lancet, Vol. 1, No. 8024, 1977, p. 1260.
[18]	G. Lose, O. Lalos, R. M. Freeman and P. van Kerrebroeck, “Nocturia Study Group. Efficacy of Desmopressin (Minirin) in the Treatment of Nocturia: A Double-Blind Placebo-Controlled Study in Women,” American Journal of Obstetrics & Gynecology, Vol. 189, No. 4, 2003, pp. 1106-1113. doi:10.1067/S0002-9378(03)00593-3
[19]	S. Salvatore, M. Soligo, F. Proietti, S. Citterio, W. Artibani and R. Milani, “Overactive Bladder Syndrome: Considerations in Pharmacotherapy and New Perspectives,” European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 120, No. 2, 2005, pp. 129-133. doi:10.1016/j.ejogrb.2004.10.014